Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.

Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K.

Clin Cancer Res. 2009 Apr 1;15(7):2523-30. doi: 10.1158/1078-0432.CCR-08-1403. Epub 2009 Mar 10.

2.

[Rituximab resistance in B-cell lymphoma and its elimination].

Hatake K, Terui Y.

Gan To Kagaku Ryoho. 2009 Apr;36(4):548-51. Japanese.

PMID:
19381025
3.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x. Epub 2008 Nov 25.

4.
5.

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD.

Haematologica. 2009 Mar;94(3):423-7. doi: 10.3324/haematol.2008.001024. Epub 2009 Feb 11.

6.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T.

Blood. 2009 May 14;113(20):4885-93. doi: 10.1182/blood-2008-08-175208. Epub 2009 Feb 26.

7.

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.

Ann Hematol. 2003 Sep;82(9):585-8. Epub 2003 Jul 31.

PMID:
12898184
8.

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.

Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.

J Cutan Pathol. 2005 Oct;32(9):616-21.

PMID:
16176299
9.

Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.

Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D.

Br J Haematol. 2002 Nov;119(2):412-6.

PMID:
12406079
10.

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.

Clin Cancer Res. 2008 Mar 1;14(5):1561-70. doi: 10.1158/1078-0432.CCR-07-1254.

11.

Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.

Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B.

Oncol Rep. 2010 Oct;24(4):1101-7.

PMID:
20811695
12.

Loss of CD20 expression in relapsed lymphomas after rituximab therapy.

Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G, Bazarbachi A.

Eur J Haematol. 2003 May;70(5):330-2.

PMID:
12694172
13.

Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.

Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.

Br J Dermatol. 2005 Jul;153(1):167-73. Review.

PMID:
16029344
14.

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.

Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.

Leuk Res. 2006 May;30(5):625-31. Epub 2005 Nov 11.

PMID:
16289746
15.

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.

Clarke LE, Bayerl MG, Ehmann WC, Helm KF.

J Cutan Pathol. 2003 Aug;30(7):459-62.

PMID:
12859745
16.

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.

Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ.

Leuk Res. 2009 Jun;33(6):792-7. doi: 10.1016/j.leukres.2008.10.013. Epub 2008 Dec 2.

PMID:
19054557
17.

CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.

Pijuan L, Vicioso L, Bellosillo B, Ferrer MD, Baró T, Pedro C, Lloreta-Trull J, Munné A, Serrano S.

Am J Surg Pathol. 2005 Oct;29(10):1399-403.

PMID:
16160485
18.

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.

Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.

Clin Cancer Res. 2008 Mar 1;14(5):1550-60. doi: 10.1158/1078-0432.CCR-07-1255.

19.

[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].

Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.

Rinsho Ketsueki. 2004 Oct;45(10):1129-34. Japanese.

PMID:
15553050
20.

[Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].

Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.

Ai Zheng. 2007 Aug;26(8):837-42. Chinese.

PMID:
17697543

Supplemental Content

Support Center